Search
Bristol-Myers Squibb Co
BMYAdd to Watchlist
54.700USD
0.0000.00%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
110.11BMarket Cap
15.31P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
-2.74%
1 Month
-8.01%
6 Months
+0.07%
Year to Date
+1.41%
1 Year
+16.73%
Key Figures
54.270Open
54.730High
11.79KVolume
15.31P/E TTM
8.75P/E Dynamic
2.500Dividend TTM
0.00%Turnover Ratio
54.700Prev. Close
53.995Low
230.68KTurnover
LossP/E Static
5.96P/B
4.57%Div Yield TTM
8.13%ROA
62.88652wk High
-0.00Volume Ratio
-8.95BNet Profit
2.01BShares
3.5723EPS TTM
0.24Beta
38.84%ROE
42.52052wk Low
1.34%Amplitude
66.53%Gross Margin
110.11BMarket Cap
-5.98Reward/Risk
1.36%Risk Rate
TradingKey Stock Score of Bristol-Myers Squibb Co
Currency: USD Updated: 2026-06-22Key Insights
Bristol-Myers Squibb Co's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 54 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 62.06.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bristol-Myers Squibb Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
46°C
Very Low
Very High
Neutral
Bristol-Myers Squibb Co Highlights
StrengthsRisks
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 15.31, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.72B shares, decreasing 0.65% quarter-over-quarter.
Held by Richard Pzena
Star Investor Richard Pzena holds 17.91M shares of this stock.
Analyst Rating
Based on
32
analysts
Hold
Current Rating
62.057
Target Price
+14.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bristol-Myers Squibb Co Info
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Ticker SymbolBMY
CompanyBristol-Myers Squibb Co
CEOBoerner (Christopher S)
Websitehttps://www.bms.com
Related Instruments
+0.33%
+1.20%
+1.28%
0.00%
+1.22%
0.00%
0.00%
+1.24%
0.00%
-0.44%
+0.01%
0.00%
0.00%
+1.92%
0.00%
0.00%
+0.80%
0.00%
0.00%Popular Instruments
73.265
-0.724 (-0.98%)
295.000
-2.010 (-0.68%)
204.000
-4.650 (-2.23%)
4120.390
-69.860 (-1.67%)
682.930
-49.690 (-6.78%)
2089.000
-184.730 (-8.12%)
1129.500
-81.880 (-6.76%)
344.000
-5.680 (-1.62%)
62284.870
-2118.930 (-3.29%)
396.380
-8.670 (-2.14%)
FAQs
What is the current price of Bristol-Myers Squibb Co (BMY)?
The current price of Bristol-Myers Squibb Co (BMY) is 54.70.
What is the symbol of Bristol-Myers Squibb Co?
The ticker symbol of Bristol-Myers Squibb Co is BMY.
What is the 52-week high of Bristol-Myers Squibb Co?
The 52-week high of Bristol-Myers Squibb Co is 62.89.
What is the 52-week low of Bristol-Myers Squibb Co?
The 52-week low of Bristol-Myers Squibb Co is 42.52.
What is the market capitalization of Bristol-Myers Squibb Co?
The market capitalization of Bristol-Myers Squibb Co is 111.70B.
Is Bristol-Myers Squibb Co (BMY) currently rated as Buy, Hold, or Sell?
According to analysts, Bristol-Myers Squibb Co (BMY) has an overall rating of signal_hold, with a price target of 62.06.
What is the Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY)?
The Earnings Per Share (EPS TTM) of Bristol-Myers Squibb Co (BMY) is 3.47.
